INTRODUCTION {#sec1}
============

Human athletic performance is a multifactorial trait determined by the interaction of genetic and environmental factors. It is estimated that around 66% of the variance in athletic status could be explained by genetic factors \[[@cit0001]\]. The remaining variance is dependent on environmental factors, such as physical training, nutrition, and technological support. With the development of molecular research in sport, at least 155 genetic variants have been found to be associated with athletic performance, with the angiotensin converting enzyme (*ACE*) gene I/D and the alpha actinin-3 (*ACTN3*) gene R577X polymorphisms having been the most extensively studied \[[@cit0002]--[@cit0004]\]. However, partly owing to the small sample size of studies, a considerable number of these proposed associations have not been consistently replicated in independent investigations by different teams of researchers \[[@cit0005]\].

*PPARGC1A* has been suggested to be associated with athletic performance because of its role in a wide variety of biological responses \[[@cit0006], [@cit0007]\]. It encodes peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α), a transcriptional coactivator of the peroxisome proliferator-activated receptor (PPAR) family. PGC1α regulates the expression of several key genes involved in glucose and fatty acid oxidation \[[@cit0008], [@cit0009]\]. It is also a key stimulator of mitochondrial biogenesis by activating transcription of the nuclear respiratory factors NRF1 and NRF2, inducing expression of mitochondrial transcription factor A (TFAM) \[[@cit0010]\]. PGC1α is also important for skeletal muscle fibre conversion. Over-expression of *PPARGC1A* leads to the conversion of fast-twitch type IIb muscle fibres to type IIa and slow-twitch type I fibres by 20% and 10%, respectively \[[@cit0011]\]. Furthermore, *PPARGC1A* expression correlates with both short-term exercise and endurance training in rodents and humans \[[@cit0012]--[@cit0014]\].

The *PPARGC1A* gene is located on chromosome 4 (4p15.2). The Gly482Ser (rs8192678) polymorphism is the most frequently analyzed of all the gene variations that have been discovered. The polymorphism has been reported to be associated with type 2 diabetes, obesity and elevated blood pressure \[[@cit0015]--[@cit0017]\]. In three case-control studies, a significantly lower frequency of the Ser allele has been reported in elite endurance athletes compared with sedentary controls \[[@cit0018]--[@cit0020]\]. However, several other studies have failed to replicate the same association \[[@cit0021]--[@cit0026]\]. Furthermore, two studies observed a higher frequency of the Gly/Gly genotype in power athletes \[[@cit0020], [@cit0024]\]. Therefore, no definitive conclusions have been drawn about the relationship between the *PPARGC1A* Gly482Ser polymorphism and athletic performance. Tharabenjasin et al. recently reported the results of a meta-analysis about the association of the *PPARGC1A* Gly428Ser polymorphism with athletic ability and sports performance \[[@cit0027]\].

The aim of this study is to summarize the association between the *PPARGC1A* Gly482Ser polymorphism and athletic performance by conducting meta-analyses, which might provide a more definitive answer compared with individual research reports.

MATERIALS AND METHODS {#sec2}
=====================

Literature identification {#sec2.1}
-------------------------

All procedures involved in the meta-analyses were carried out in accordance with the PRISMA guidelines \[[@cit0028]\]. A comprehensive literature search was performed using the PubMed and Web of Science databases, from inception to September 2018. The combination of the following keywords was used: "*PPARGC1A* or PGC1α", "polymorphisms", "rs8192678" and "sports". No language limitations or publication restrictions were applied to the search strategy.

Inclusion and exclusion criteria {#sec2.2}
--------------------------------

Studies that reported the distribution of *PPARGC1A* polymorphism among both athletes and sedentary controls were considered. If the same data were presented in multiple studies, the highest quality study was included. Exclusion criteria were: (i) review articles or conference literatures; (ii) studies involving animal experiments, or the target population was not athletes; (iii) articles did not provide sufficient original data; (iv) genotype distribution deviated from Hardy--Weinberg equilibrium (HWE) in the control group; (v) studies only concerning mixed endurance-power type of sports, such as football.

Quality assessment {#sec2.3}
------------------

The Newcastle-Ottawa Scale (NOS) was used to evaluate the methodological quality of the included studies by two reviewers independently \[[@cit0029]\]. Each study was assessed and scored based on three aspects: case and control selection, comparability, and exposure. NOS score ranges from 0 to 9 stars. Studies that scored seven or more stars were considered to be of high quality.

Statistical analysis {#sec2.4}
--------------------

Hardy--Weinberg equilibrium was examined in controls for each study by Pearson's chi-squared test. Heterogeneity across the studies was assessed by the *I* square statistic (*I* ^2^), with *I* ^2^ \< 50% indicating reduced statistical difference \[[@cit0030]\]. A fixed-effects model was used in cases of low statistical heterogeneity, otherwise a random-effects model was applied \[[@cit0031], [@cit0032]\]. The association between polymorphism and athletic performance was estimated by calculating the odds ratio (OR) with corresponding 95% confidence interval (95% CI), comparing athletes and controls. Potential publication bias was examined by Begg's and Egger's tests and funnel plots \[[@cit0033], [@cit0034]\]. Sensitivity analysis was also conducted to examine the stability of the overall results by sequential exclusion of one study at a time. All statistical analyses were conducted with STATA software (version 15, StataCorp, College Station, Texas).

RESULTS {#sec3}
=======

The initial search of electronic databases identified 245 unduplicated articles. As shown in [Figure 1](#f0001){ref-type="fig"}, after excluding articles whose titles were not relevant, 29 abstracts were retrieved for the next step. After abstract evaluation, 22 articles were included in a more detailed full text evaluation \[[@cit0035]--[@cit0041]\]. Then 12 articles were excluded \[[@cit0042]--[@cit0053]\]. Ultimately 10 articles were included in this study ([Fig. 1](#f0001){ref-type="fig"}).

![Flow diagram of literature search and screen.](JBS-36-88752-g001){#f0001}

The 10 studies involved a total of 3,708 athletes and 6,228 controls. The athletes were divided into endurance-type and power-type groups in accordance with their sporting discipline \[[@cit0004]\]. The endurance group included athletes who participated in marathon, biathlon, long-distance swimming, pentathlon, rowing, long-distance running, road cycling, cross-country skiing, long-distance track and field athletics, triathlon, race walking and mountain biking. The power group included athletes involved in sprinting, weightlifting, short-distance track and field athletics, powerlifting, kayaking, judo, wrestling, boxing, fencing, short-distance swimming, alpine skiing, artistic gymnastics, and throwing and jumping events. It should be pointed out that no clear-cut distinction can be drawn between endurance and power sports. There are elements of power in the endurance sports mentioned, as there are endurance elements in power sports. All the power athletes were from Caucasian populations. The data for athletes who participated in mixed-type sports were not extracted from the studies included.

For all articles, the following data were extracted from original publications: first author and year of publication, country of the study, total number of athletes and controls, type of athletes and controls, race of participants, and genotype and allele frequencies among athletes and controls and for each of the subgroups ([Table 1](#t0001){ref-type="table"} and [Table 2](#t0002){ref-type="table"}). The results of HWE tests demonstrated that the genotype distributions in controls were all in HWE (all *P* \> 0.05). And according to the quality criteria, the NOS score for all articles is greater than or equal to 7, except for one article \[[@cit0023]\]. Two meta-analyses were carried out with the endurance group and power group.

###### 

Summary of primary data for association between *PPARGC1A* Gly482Ser polymorphism and endurance performance.

  Authors              Year        Country        Ethnicity   Group          Number (N)   Genotype (N)   MAF     *P*~HWE~   NOS Score            
  -------------------- ----------- -------------- ----------- -------------- ------------ -------------- ------- ---------- ----------- -------- ---
  Lucia et al.         2005        Spain          Caucasian   Case Control   104          52             43      9          0.293       1.0000   7
  100                  36          48             16          0.400                                                                              
  Eynon et al.         2010        Israeli        Caucasian   Case Control   74           37             37      0          0.250       0.9529   7
  240                  79          117            44          0.427                                                                              
  Muniesa et al.       2010        Spanish        Caucasian   Case Control   141          65             52      24         0.355       0.2261   7
  123                  47          63             13          0.362                                                                              
  Ginevičienė et al.   2011        Lithuanian     Caucasian   Case Control   77           40             33      4          0.266       0.5177   9
  250                  129         104            17          0.276                                                                              
  Maciejewska et al.   2012        Polish         Caucasian   Case Control   84           46             34      4          0.250       0.8938   8
  684                  280         314            90          0.361                                                                              
  Russian              Caucasian   Case Control   548         273            239          36             0.284   0.6651                          
  1132                 489         505            138         0.345                                                                              
  He et al.            2015        Chinese        Asian       Case Control   235          73             115     47         0.445       0.6321   7
  504                  156         244            104         0.448                                                                              
  Yvert et al.         2016        Japanese       Asian       Case Control   175          45             87      43         0.494       0.8741   8
  649                  191         324            134         0.456                                                                              
  Peplonska et al.     2017        Polish         Caucasian   Case Control   225          102            105     18         0.313       0.0871   6
  451                  199         213            39          0.323                                                                              
  Guilherme et al.     2018        Brazilian      Caucasian   Case Control   316          153            140     23         0.294       0.6187   7
  893                  428         385            80          0.305                                                                              

MAF = minor allele frequency, *P* ~HWE~ = *P* value for Hardy--Weinberg equilibrium of controls, NOS = Newcastle-Ottawa Scale.

###### 

Summary of primary data for association between *PPARGC1A* Gly482Ser polymorphism and power performance.

  Authors              Year        Country        Ethnicity   Group          Number (N)   Genotype (N)   MAF     *P*~HWE~   NOS Score            
  -------------------- ----------- -------------- ----------- -------------- ------------ -------------- ------- ---------- ----------- -------- ---
  Eynon et al.         2010        Israeli        Caucasian   Case Control   81           35             36      10         0.346       0.9529   7
  240                  79          117            44          0.427                                                                              
  Ginevičienė et al.   2011        Lithuanian     Caucasian   Case Control   51           29             21      1          0.225       0.5177   9
  250                  129         104            17          0.276                                                                              
  Maciejewska et al.   2012        Polish         Caucasian   Case Control   210          118            79      13         0.25        0.8938   8
  684                  280         314            90          0.361                                                                              
  Russian              Caucasian   Case Control   724         329            322          73             0.323   0.6651                          
  1132                 489         505            138         0.345                                                                              
  Gineviciene et al.   2016        Russian        Caucasian   Case Control   114          62             35      17         0.303       0.7450   8
  947                  424         416            107         0.333                                                                              
  Lithuanian           Caucasian   Case Control   47          24             22           1              0.255   0.4860                          
  255                  132         106            17          0.275                                                                              
  Peplonska et al.     2017        Polish         Caucasian   Case Control   188          97             73      18         0.290       0.0871   6
  451                  199         213            39          0.323                                                                              
  Guilherme et al.     2018        Brazilian      Caucasian   Case Control   314          173            116     25         0.264       0.6187   7
  893                  428         385            80          0.305                                                                              

MAF = minor allele frequency, *P* ~HWE~ = *P* value for Hardy--Weinberg equilibrium of controls, NOS = Newcastle-Ottawa Scale.

As shown in [Fig. 2A](#f0002){ref-type="fig"}, a higher frequency of the Gly/Gly genotype was observed in endurance athletes compared to controls in Caucasian populations. The combined OR for the Gly/Gly genotype compared to the Gly/Ser + Ser/Ser genotype was 1.26 (95% CI, 1.11--1.42). The degree of heterogeneity across the studies was moderate (*I* ^2^ = 38.5%). There was no significance observed in Asian endurance athletes (OR, 0.92; 95% CI, 0.72--1.19). A higher frequency of the Gly allele (OR, 1.29; 95% CI, 1.09--1.52) was also observed in Caucasian endurance athletes, but not in Asian counterparts (OR, 0.94; 95% CI, 0.80--1.11; [Fig. 2B](#f0002){ref-type="fig"}).

![Meta-analysis of the association between endurance performance and PPARGC1A Gly482Ser polymorphism. (A) Gly/Gly vs. Gly/Ser+Ser/Ser; (B) (Allele Gly vs. Ser). CI= confidence interval; OR= odds ratio. \*Different study population from the same article.](JBS-36-88752-g002){#f0002}

[Fig. 3](#f0003){ref-type="fig"} shows the results of the overall associations between the *PPARGC1A* Gly482Ser polymorphism and power performance. A significant correlation was found for the Gly/Gly genotype in athletes compared to controls (OR, 1.30; 95% CI, 1.16--1.46; [Fig. 3A](#f0003){ref-type="fig"}). The degree of heterogeneity across studies was low (*I* ^2^ = 29.3%). A higher frequency of the Gly allele was also observed in power athletes (OR, 1.22; 95% CI, 1.12--1.33; [Fig. 3B](#f0003){ref-type="fig"}). Here, the degree of heterogeneity across studies was also low (*I* ^2^ = 28.9%).

![Meta-analysis of the association between power performance and PPARGC1A Gly482Ser polymorphism. (A) Gly/Gly vs. Gly/Ser+Ser/Ser; (B) (Allele Gly vs. Ser). CI= confidence interval; OR= odds ratio. \*Different study population from the same article.](JBS-36-88752-g003){#f0003}

Publication bias was assessed by Begg's and Egger's tests and funnel plots. There was no obvious asymmetry in the Begg's funnel plot ([Figure 4](#f0004){ref-type="fig"}). The results of Begg's test (Gly/Gly vs. Gly/Ser+Ser/Ser for endurance performance: *P* = 0.269; allele Gly vs. Ser for endurance performance: *P* = 0.066; Gly/Gly vs. Gly/Ser+Ser/Ser for power performance: *P* = 1.0; allele Gly vs. Ser for power performance: *P* = 1.0) and Egger's test (Gly/Gly vs. Gly/Ser+Ser/Ser for endurance performance: *P* = 0.093; allele Gly vs. Ser for endurance performance: *P* = 0.200; Gly/Gly vs. Gly/Ser+Ser/Ser for power performance: *P* = 0.481; allele Gly vs. Ser for power performance: *P* = 0.525) also suggested no statistically significant publication bias.

![Begg's funnel plot for eligible studies of association between PPARGC1A Gly482Ser polymorphism and athletic performance. (A) Homozygotes Gly/Gly vs. Gly/Ser+Ser/Ser for endurance performance; (B) Allele Gly vs. Ser for endurance performance; (C) Homozygotes Gly/Gly vs. Gly/Ser+Ser/Ser for power performance; (D) Allele Gly vs. Ser for power performance. OR= odds ratio.](JBS-36-88752-g004){#f0004}

Sensitivity analysis was performed to evaluate the effect of each included study on the overall results. One study was excluded each time. Then pooled ORs were recomputed and compared with the overall OR. Significant associations between the *PPARGC1A* Gly allele and endurance performance were not observed after excluding the Maciejewska et al. article \[[@cit0020]\] ([Fig. 5A](#f0005){ref-type="fig"}; [Fig. 5B](#f0005){ref-type="fig"}). It indicated that the results were unstable. Moreover, the overall results of the associations between *PPARGC1A* Gly482Ser polymorphism and power performance were rather stable ([Fig. 5C](#f0005){ref-type="fig"}; [Fig. 5D](#f0005){ref-type="fig"}).

![Sensitivity analysis of the association PPARGC1A Gly482Ser polymorphism and athletic performance. (A) Homozygotes Gly/Gly vs. Gly/Ser+Ser/Ser for endurance performance; (B) Allele Gly vs. Ser for endurance performance; (C) Homozygotes Gly/Gly vs. Gly/Ser+Ser/Ser for power performance; (D) Allele Gly vs. Ser for power performance. \*Different study population from the same article.](JBS-36-88752-g005){#f0005}

DISCUSSION {#sec4}
==========

*PPARGC1A* encodes a key regulator of cellular energy metabolism. This study estimated the association of human athletic performance with *PPARGC1A* Gly482Ser polymorphism by means of meta-analysis. The main finding of the current study is that higher frequencies of the Gly/Gly genotype 1.26 (95% CI, 1.11--1.42) and the Gly allele (OR, 1.29; 95% CI, 1.09--1.52) were observed in Caucasian endurance athletes, but not in Asian counterparts. Furthermore, higher incidences of the Gly/Gly genotype (OR, 1.30; 95% CI, 1.16--1.46) and the Gly allele (OR, 1.22; 95% CI, 1.12--1.33) were observed in power athletes compared to controls.

To date, the results of individual studies on the associations between the *PPARGC1A* Gly482Ser polymorphism and athletic performance have been discrepant. Lucia et al. first detected a significantly lower frequency of the Ser allele in Spanish endurance athletes \[[@cit0018]\]. A later study supported this association \[[@cit0019], [@cit0020]\], although there were also some exceptions \[[@cit0021]--[@cit0026]\]. One of the greatest limitations of these case--control association studies is their small sample size, which often leads to statistical insignificance and results in controversial conclusions. The current meta-analyses overcame this limitation by combining the findings from 10 studies. The analyses involved 3,708 athletes and 6,228 controls. The results revealed that higher frequencies of the Gly/Gly genotype and the Gly allele were observed in Caucasian endurance and power athletes. Thus, the study provides solid evidence for an association between *PPARGC1A* polymorphism and athletic performance.

It is interesting to note that higher frequencies of the Gly/Gly genotype and the Gly allele of the *PPARGC1A* Gly482Ser polymorphism were found in both endurance athletes and power athletes from Caucasian populations. Endurance sports are generally considered to mainly use the aerobic energy system to produce energy, while power sports rely mostly on anaerobic metabolism as the energy source \[[@cit0054]\]. However, they are not totally distinct entities. Modern endurance sports also require very powerful muscle contractions at competitively critical stages \[[@cit0055]\], while the contribution of the aerobic energy system to some kinds of speed/power sports is considerable \[[@cit0056]\]. A previous study demonstrated that the Ser allele is associated with lower expression of *PPARGC1A* \[[@cit0057]\]*.* Several studies have shown the effect of Gly482Ser polymorphism on the functional activity of PGC1α, but the results are controversial. Choi et al. firstly suggested that the PGC1α 482Gly variant had impaired co-activator activity on the *TFAM* promoter \[[@cit0058]\]. In contrast, Okauchi et al. reported no difference in activity between the variants when activating the adiponectin promoter \[[@cit0059]\]. A study performed by Michael et al. demonstrated that PGC1α could bind to and co-activate the muscle-selective transcription factor (MEF) 2C, then increased the expression of glucose transporter 4 (*GLUT4*) \[[@cit0060]\]. Also, the change from Gly to Ser at position 482 in PGC1α decreased its binding interaction with MEF2C \[[@cit0061]\]. Thus, the decreased interaction might impair the GLUT4 insulin-stimulated glucose uptake, which would then affect glycogen synthesis and the subsequent synthesis of fatty acids. Finally, the PGC1α 482Ser variant might weaken the efficiency of aerobic metabolism. Moreover, the Pgc1α/Mef2c complex could bind to the *Ppargc1a* promoter and activate it \[[@cit0062]\]. So the decreased interaction between PGC1α/MEF2C might decrease the expression of *PPARGC1A* itself. Therefore, the Gly allele of the Gly482Ser polymorphism may facilitate athletic performance through increasing the expression of *PPARGC1A* and enhancing the efficiency of aerobic metabolism.

Although the current study was about a similar topic as a recently published meta-analysis \[[@cit0027]\], this study contributes to the *PPARGC1A* research in athletic performance. First, the present study corrects the mistakes that appeared in the Tharabenjasin et al. study. This study excluded articles that there were duplicate genotype data of athletes or controls. For example, genotype data of 1132 Russian controls and partial Russian athletes were duplicated between the Ahmetov et al. article and Maciejewska et al. article \[[@cit0020], [@cit0052]\]. Duplicate data may affect overall results, especially when it comes to large samples. Thus only the Maciejewska et al. article was included in this study. By contrast, both articles were included in the Tharabenjasin et al. study. Second, the results of this study indicated that endurance-type and power-type sports might have more in common than was generally believed regarding the genetic background, especially when a specific gene polymorphism was taken into account.

Several limitations should be considered in interpreting the results of this study. First, owing to the inconsistent definition of endurance events among some studies, phenotypic heterogeneity cannot be completely avoided. Second, owing to the different standards of elite, sub-elite and non-elite athletes, the present study did not consider the potential confounding effects of performance levels. In addition, Begg's and Egger's tests as well as funnel plots were used to assess publication bias in this study, whereas such tests have low power when applied to studies whose number is \< 10 \[[@cit0063]\]. Finally, because not all the relevant data could be obtained from the included studies, further detailed sub-analysis was limited. For example, if the athletes could have been subdivided into male and female groups, more comprehensive results could be presented.

CONCLUSIONS {#sec5}
===========

In conclusion, the current meta-analyses based on 10 studies revealed that higher frequencies of the Gly/Gly genotype and the Gly allele of the *PPARGC1A* Gly482Ser polymorphism were observed in Caucasian endurance athletes, and the Gly/Gly genotype and the Gly allele were significantly associated with power athletes compared to controls. The results demonstrate that the Gly/Gly genotype and the Gly allele of the *PPARGC1A* Gly482Ser polymorphism may facilitate athletic performance regardless of the type of sport. This finding also provides solid evidence to support the possible influence of genetic factors on human athletic performance.
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